Bristol/ImClone Erbitux BLA Timeline Depends On Merck KGaA Phase II Study

ImClone's timeline for refiling its Erbitux BLA hinges on completion of Merck KGaA's Phase II study in colorectal cancer patients

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet